What Happened?
New York, NY-based Ohr Pharmaceutical Promoted Jason Slakter as Chief Technology Officer
About the Company
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.
About the Person
Irach B. Taraporewala, BS, M.S., PhD, has been the Chief Technology Officer of since August 7, 2015. Dr. Taraporewala served as the Chief Executive Officer of Ohr Pharmaceutical, Inc. from April 12, 2010 to August 7, 2015, and served as its President until August 7, 2015. Dr. Taraporewala Founded Ohr Pharmaceutical, Inc. He served as Vice President of Regulatory Affairs and Clinical Research of Mystic Pharmaceuticals Inc. since May 2008. He has twenty years experience in drug development and regulatory affairs within the pharmaceutical industry. He served as Senior Consultant in the Drug Development Consulting division of Boston-based PAREXEL International Corp. He has also served as Principal Investigator on four National Institute of Health and U.S. Department of Defense-funded biomedical research grants on antiviral drugs, DNA-based cancer diagnostics and on antimalarial compound development. From 1998 to 2004, Dr. Taraporewala served as Director of Chemistry and Quality Control at Yonkers, where he helped take OHR/AVR118, an immunomodulator drug, into clinical trials for AIDS, cancer cachexia and rheumatoid arthritis. Dr. Taraporewala worked in research and development at Ciba-Geigy, which later merged with Sandoz to become Novartis. Dr. Taraporewala has held senior level scientific and management positions with: Lipitek International and the Southwest Foundation for Biomedical Research. He has been a Director of Ohr Pharmaceutical, Inc. since 2012. He holds a PhD in Organic/Medicinal Chemistry from Philadelphia College of Pharmacy and Science, Dr. Taraporewala holds three issued patents, four pending patents, has twenty-one published research papers and has lectured extensively. He earned his PhD in Organic/Medicinal Chemistry from Philadelphia College of Pharmacy and Science. He holds an MS in Organic Chemistry and BS in Chemistry/Microbiology from the University of Bombay.
Info Source
News
Short Profile